Do you want to read an article? Please log in or register.
The impact of ARID1A mutation on molecular characteristics in colorectal cancer
Gastrointestinal Cancer
RECOMMENDED
Related content
Gastrointestinal Cancer
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
Annals of Oncology
Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Krichner T, Tannapfel A, Reinacher-Schick A
Gastrointestinal Cancer
The prognostic impact of Consensus Molecular Subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial
Ann Oncol.
Mooi JK, Wirapati P, Asher R, Lee CK, Savas PS, Price TJ, Townsend A, Hardingham J, Buchanan D, Williams D, Tejpar S, Mariadason JM, Tebbutt NC
doi: 10.1093/annonc/mdy410.
Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer
JAMA Oncol.
Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Liyanarachchi S, Kalady M, Heald B, Greenwood C, Paquette I, Prues M, Draper DJ, Lindeman C, Kuebler JP, Reynolds K, Brell JM, Shaper AA, Mahesh S, Buie N, Weeman K, Shine K, Haut M, Edwards J, Bastola S, Wickham K, Khanduja KS, Zacks R, Pritchard CC, Shirts BH, Jacobson A, Allen B, de la Chapelle A, Hampel H; Ohio Colorectal Cancer Prevention Initiative Study Group
doi: 10.1001/jamaoncol.2016.5194
Gastrointestinal Cancer
A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer
J Surg Oncol.
Sho S, Court CM, Winograd P, Russell MM, Tomlinson JS
doi: 10.1002/jso.24781.
Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches
Cancer Treatment Reviews
Strickler JH, Wu C, Bekaii-Saab T
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
J Clin Oncol.
Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S
doi: 10.1200/JCO.2016.71.0012.
Gastrointestinal CancerFurther Publications
Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020
★ 3
Recommended and commented by
Alexander Meisel, Faculty Member
healthbook TIMES Oncology Hematology
Corresponding author:
Dr Alexander Siebenhüner
Senior Consultant in Medical Oncology
Cantonal Hospital Schaffhausen
Schaffhausen, Switzerland
Gastrointestinal Cancer
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial
Eur J Cancer.
Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, Twombly TS, Mima K, Morikawa T, Song M, Nowak JA, Nishihara R, Saltz LB, Niedzwiecki D, Ou FS, Zemla T, Mayer RJ, Baba H, Ng K, Giannakis M, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Meyerhardt JA, Ogino S
doi: 10.1016/j.ejca.2019.01.022.
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.